Spero Therapeutics (SPRO) Non-Current Assets (2016 - 2026)

Spero Therapeutics has reported Non-Current Assets for 11 years, with the latest figure at $1.4 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 52.95% year-over-year to $1.4 million; the trailing twelve-month figure through Mar 2026 stood at $7.6 million (down 79.7% YoY), and the FY2025 full-year result was $1.6 million, down 50.02% from the prior year.
• Non-Current Assets for Q1 2026 stood at $1.4 million, down from $1.6 million in the prior quarter.
• The five-year high for Non-Current Assets was $51.2 million in Q4 2023, with the low at $1.4 million in Q1 2026.
• Historically, Non-Current Assets has averaged $11.6 million across 5 years, with a median of $10.5 million in 2023.
• Annual changes were most pronounced in 2023 — Non-Current Assets soared 355.68% — and 2024, when it tumbled 93.62%.
• Spero Therapeutics' Non-Current Assets stood at $11.2 million in 2022, then surged by 355.68% to $51.2 million in 2023, then plunged by 93.62% to $3.3 million in 2024, then sank by 50.02% to $1.6 million in 2025, then retreated by 13.72% to $1.4 million in 2026.
• The last three Non-Current Assets figures came in at $1.4 million (Q1 2026), $1.6 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.